Boston Scientific (BSX) Asset Writedowns and Impairment (2010 - 2025)

Boston Scientific's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at -$27.0 million for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment fell 164.29% year-over-year to -$27.0 million; the TTM figure through Dec 2025 stood at -$204.0 million (up 12.82% YoY), while the FY2025 annual figure was $46.0 million, down 36.11% from the prior year.
• Asset Writedowns and Impairment came in at -$27.0 million for Q4 2025 at Boston Scientific, down from $27.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $197.0 million in Q4 2021 to a low of -$246.0 million in Q3 2024.
• A 5-year average of $26.1 million and a median of $34.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 235.48% in 2024 and fell as far as 24700.0% in 2024.
• Boston Scientific's Asset Writedowns and Impairment stood at $197.0 million in 2021, then slumped by 36.55% to $125.0 million in 2022, then plunged by 124.8% to -$31.0 million in 2023, then surged by 235.48% to $42.0 million in 2024, then tumbled by 164.29% to -$27.0 million in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$27.0 million, $27.0 million, and $42.0 million for Q4 2025, Q3 2025, and Q4 2024 respectively.

Peer Comparison